Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
Public ClinicalTrials.gov record NCT05137314. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Open-Label, Dose-Escalating Study to Evaluate the Safety and Tolerability of PLG0206 in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to learn about the safety and effects of PLG0206 for treating periprosthetic joint infections (PJI) in conjunction with the DAIR (debridement, antibiotics and implant retention) surgical procedure for patients with periprosthetic joint infections (PJI) after total knee arthroplasty (TKA) .
Study identification
- NCT ID
- NCT05137314
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 14 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2022 (Actual)
- Primary completion
- Mar 19, 2024 (Actual)
- Completion
- Mar 19, 2024 (Actual)
- Last update posted
- May 21, 2025
2022 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford Hospital | Palo Alto | California | 94305 | — |
| Gulfcoast Research | Sarasota | Florida | 34232 | — |
| LifeBridge | Baltimore | Maryland | 21215 | — |
| Brigham & Women's Hospital | Boston | Massachusetts | 02115 | — |
| NYU Langone Orthopedic Hospital | New York | New York | 10003 | — |
| Cleveland Clinic | Cleveland | Ohio | 44106 | — |
| Ohio State University | Columbus | Ohio | 43203 | — |
| Rothman | Philadelphia | Pennsylvania | 19107 | — |
| Memorial Hermann Hospital | Houston | Texas | 77030 | — |
| Michael E. DeBakey VA Medical Center | Houston | Texas | 77030 | — |
| University of Utah Orthopaedic Center | Salt Lake City | Utah | 44106 | — |
| WVU | Morgantown | West Virginia | 26501 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05137314, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 21, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05137314 live on ClinicalTrials.gov.